

FOR IMMEDIATE RELEASE

First Patient Enrolled in Phase II Clinical Study of Istaroxime in Italy

Hong Kong, 3rd October 2013 – CVie Therapeutics Company Limited (“CVie”), a subsidiary of Lee’s Pharmaceutical Holdings Limited (“the Group”) (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the first patient for Istaroxime’s global phase II clinical study (Protocol No. CVT-CV-002) has been enrolled in Italy.

Istaroxime is a first-in-class luso-inotropic agent under development for the treatment of acute decompensated heart failure. It possesses a dual mode of action, combining inotropic (myocyte contraction) and lusitropic (myocyte relaxation) effects. Istaroxime is a potent positive inotropic agent that increases myocardial contractility through inhibition of Na^+/K^+ -ATPase, subsequently augmenting cytoplasmic calcium levels. And based on its mechanism of action, preclinical studies and early clinical findings, it is anticipated that Istaroxime at the doses proposed in this trial will be devoid of the deleterious effects of conventional inotropes. Istaroxime does not increase heart rate (HR), minimizes the increase in oxygen consumption, is less arrhythmogenic and does not cause hypotension.

This is a global phase II multi-centers, randomized, double-blinded, paralleled and placebo-controlled clinical study with an Italian arm and a Chinese arm. The study aims to assess the safety, tolerability and efficacy of two different doses of Istaroxime (0.5 and 1.0 $\mu\text{g}/\text{kg}/\text{min}$) by intravenous infusion for 24 hours in comparison with placebo in treatment of Chinese and Caucasian patients with acute decompensated heart failure. It is targeted to enroll a total of 120 patients.

“We are pleased to have reached this important milestone for Istaroxime,” said Dr. Benjamin Li, Chief Executive Officer. “The start of Italian arm is expected to be followed by initiation of Chinese arm in the first half of next year.”

About CVie

CVie Therapeutics Company Limited is a joint venture between Lee’s Pharmaceutical Holdings Ltd. and a reputable US venture capital and is a stand-alone drug development company specialized in cardiovascular diseases. CVie owns two phase II assets that target cardiovascular disease with significant unmet medical need. CVie has successfully filed to the CFDA the application for a global phase IIb clinical study in China for Rostafuroxin for hypertension in August 2012 and Istaroxime for acute decompensated heart failure in May 2013.



FOR IMMEDIATE RELEASE

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com